Independent Evaluation Confirms Breakthrough Performance of BioLargo's Cellinity Battery Technology for Grid-Scale Energy Storage

BioLargo, Inc. (OTCQX:BLGO), a company that creates and commercializes sustainable technologies to solve tough environmental and cleantech challenges, announced that a third-party evaluation has confirmed key advantages for its Cellinity battery technology's use in grid-scale battery energy storage applications.
The evaluation was conducted by U.S. BESS Corporation (www.usbesscorp.com), an expert provider of advanced energy storage solutions for critical infrastructure applications spanning utilities, defense, microgrids, and heavy industry.
U.S. BESS senior technical staff performed an examination of Cellinity's design and assembly protocols, inspection of testing infrastructure, review of data from test results, and an assessment of methodologies used for performance characterization, concluding that the following performance characteristics exclusive of any auxiliary systems are supported by their observations and are reasonably representative of the current Cellinity cell's demonstrated behavior:
Open circuit voltage: > 4.2 V
Operating temperature range: from 120°C to 250°C
Energy density: > 500 Wh/kg (calculated based on active material)
Power density: > 500 mW/cm 3 (maximum observed value of 1579 W/kg at 230°C)
Charge capacity: Cell can be charged to 100% of theoretical capacity
Charge/discharge efficiency: ~100%
Energy efficiency: 95% at 230°C; 87% at 120°C
Self-discharge: No measurable self-discharge observed over test durations
Thermal cycling durability: Performance unaffected after repeated cycling
U.S. BESS Corp further concluded that it is reasonable to claim that a) the cell would not experience any thermal runaway, b) materials of construction are commonly available and can be domestically sourced, c) the cell does not contain any rare earth elements, and d) cell components are fully recyclable.
A Market Ready for Disruption
The global demand for grid-scale energy storage is rapidly growing to meet the rising loads driven by artificial intelligence, decarbonization mandates, and accelerated adoption of renewables. In 2024 alone, the U.S. Energy Information Administration (www.eia.gov) reported a 66% increase in U.S. battery energy storage capacity. While lithium-ion batteries currently dominate the market, they present known challenges: fire risks from thermal runaway, efficiency losses over time, and sourcing constraints related to rare and critical minerals.
BioLargo's Cellinity battery technology (www.biolargoenergy.com) overcomes these limitations by leveraging novel materials and architecture to deliver both exceptional thermal performance and operational efficiencywithout relying on rare earth elements.
Validation Supports Commercial Pathway
The U.S. BESS report concludes: 'Based on our inspection and the evidence provided, U.S. BESS finds that the Cellinity Cell demonstrates a sufficient performance profile, with strong indications of high thermal stability, efficiency, energy and power density, and material sustainability, to suggest further investment in testing and commercialization. These attributes position this technology as a potential solution for critical gaps in grid-scale energy storage markets.'
Randall Moore, Chief Technology Officer at BioLargo Energy Technologies, Inc., commented, 'Our work to scale up the cell design, refine manufacturing techniques, and integrate cells into a functional module for commercial scale testing is underway.'
CEO, Dennis P. Calvert commented, 'We do not know of any long duration energy storage technology that can match Cellinity's technical claims for cost effective performance and safety. This third-party evaluation is an important piece of the puzzle for our business plan to bring Cellinity to the world through manufacturing joint ventures. We have several of these in development with potential partners and look forward to sharing more intel about those soon.'
About U.S. BESS Corp
U.S. BESS Corp is a U.S.-based company that provides energy storage solutions for a wide range of applications, including utilities, industrial needs, microgrids and defense. With decades of combined experience in battery engineering, microgrid deployment, system-level integration, and manufacturing, the company's leadership team is uniquely qualified in the battery energy storage system industry. U.S. BESS is creating the most advanced and secure battery management system and building the largest domestic battery supply in the USA.
U.S. BESS Corp Contact Information
Mark Hagedorn
CEO, U.S. BESS Corp.
503-720-9569
About BioLargo, Inc.
BioLargo, Inc. (OTCQX:BLGO) is a cleantech and life sciences innovator and engineering services solution provider. Our core products address PFAS contamination, achieve advanced water and wastewater treatment, control odor and VOCs, improve air quality, enable energy-efficiency and safe on-site energy storage, and control infections and infectious disease. Our approach is to invent or acquire novel technologies, develop them into product offerings, and extend their commercial reach through licensing and channel partnerships to maximize their impact. See our website at www.BioLargo.com.
BioLargo Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863
Safe Harbor Act
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the 'Company') expectations regarding anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the 'Risk Factors' and 'Management's Discussion and Analysis of Financial Condition and Results of Operations' sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.
SOURCE: BioLargo, Inc
View the original press release on ACCESS Newswire

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Wire

12 hours ago

• Business Wire

J.B. Poindexter & Co., Inc. Acquires Ambulance Manufacturing Leader Demers Braun Crestline Medix

HOUSTON--(BUSINESS WIRE)--J.B. Poindexter & Co., Inc. (JBPCO), a privately held North American manufacturing leader serving the commercial vehicle and specialty manufacturing industries, today announced the acquisition of Demers Braun Crestline Medix (DBCM). 'Our acquisition of DBCM aligns with JBPCO's long-term vision—building a platform of industry-leading companies with a shared commitment to quality, innovation, and customer service,' said John Poindexter, CEO and Chairman of JBPCO. Share Headquartered in Beloeil, Quebec (Canada), DBCM is one of North America's largest ambulance manufacturers with a strong presence across the U.S. and Canadian markets. Known for advanced innovation and paramedic-driven design, DBCM has delivered more than 70,000 units to over 40 countries and employs more than 1,500 team members across its operations. 'Our acquisition of DBCM aligns with JBPCO's long-term vision—building a platform of industry-leading companies with a shared commitment to quality, innovation, and customer service,' said John Poindexter, CEO and Chairman of JBPCO. 'As JBPCO celebrates its 40th anniversary, and each of the DBCM brands celebrates decades of dedication in the emergency vehicle industry, we are proud to bring together more than 500 years of combined manufacturing excellence across our portfolio of companies. DBCM has built a solid foundation, and we look forward to investing in its future, supporting the team, enhancing the products, and unlocking new opportunities for growth.' Demers recently launched its 11 th -generation ambulance platform and continues to set the bar in safety, design, and performance with paramedic-centric features like the FX Care Module. As part of JBPCO, the Company will continue to operate with brand autonomy while benefiting from expanded resources, shared capabilities, and a culture that values team member contributions. 'Joining JBPCO is a major milestone for our organization and our team,' said Alain Brunelle, CEO of Demers Braun Crestline Medix. 'We are united by a mission to improve lives, one relationship and one vehicle at a time—and this partnership ensures we can continue doing just that, with even greater scale and support.' JBPCO's total revenue will reach $3 billion with this acquisition, reinforcing its role as a cornerstone in the commercial and specialty vehicle manufacturing space—from last-mile delivery and work trucks to emergency response vehicles. About J.B. Poindexter & Co., Inc. J.B. Poindexter & Co., Inc. (JBPCO) is a privately held, diversified manufacturing company providing best-in-class commercial automotive and industrial solutions. JBPCO owns and operates a portfolio of leading business units including Morgan Truck Body, LLC; Morgan Olson, LLC; The Reading Truck Group, LLC; Truck Accessories Group, LLC d/b/a LEER Group; Masterack, LLC; EFP, LLC; Federal Eagle, LLC; and EAVX. JBPCO is headquartered in Houston, Texas and with the acquisition of DBCM, now employs more than 10,000 team members across North America. For more information, visit or connect on LinkedIn. Demers Braun Crestline Medix is one of North America's largest ambulance manufacturers, with a legacy of over 175 years across its four leading brands. Headquartered in Beloeil, Quebec, and operating in both Canada and the United States, the company designs and manufactures ambulances that meet the evolving needs of emergency service providers. Its brands—Demers, Braun, Crestline, and Medix—have delivered over 70,000 units in more than 40 countries. To learn more, visit and

Business Upturn

12 hours ago

• Business Upturn

INVESTOR DEADLINE: Rocket Pharmaceuticals, Inc. (RCKT) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

SAN DIEGO, June 20, 2025 (GLOBE NEWSWIRE) — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities between February 27, 2025 and May 26, 2025, inclusive (the 'Class Period'), have until August 11, 2025 to seek appointment as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit. Captioned Ho v. Rocket Pharmaceuticals, Inc. , No. 25-cv-10049 (D.N.J.), the Rocket Pharmaceuticals class action lawsuit charges Rocket Pharmaceuticals as well as one of Rocket Pharmaceuticals' top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. CASE ALLEGATIONS: Rocket Pharmaceuticals operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. The Rocket Pharmaceuticals class action lawsuit alleges that defendants provided investors with material information concerning Rocket Pharmaceuticals' Phase 2 pivotal trial of RP-A501 for the treatment of Danon disease while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of RP-A501's safety and clinical trial protocol; notably, that Rocket Pharmaceuticals knew Serious Adverse Events, including death of participants enrolled in the study, were a risk. In particular, Rocket Pharmaceuticals amended the trial's protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders, according to the complaint. The Rocket Pharmaceuticals class action lawsuit further alleges that on May 27, 2025, Rocket Pharmaceuticals announced that the U.S. Food and Drug Administration placed a clinical hold on the RP-A501 Phase 2 pivotal study after at least one patient suffered a Serious Adverse Event, ultimately, death, while enrolled in the study following a substantive amendment to the protocol that Rocket Pharmaceuticals failed to disclose to investors at the time management made the revision. On this news, the price of Rocket Pharmaceuticals stock fell, according to the complaint. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Rocket Pharmaceuticals securities during the Class Period to seek appointment as lead plaintiff in the Rocket Pharmaceuticals class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Rocket Pharmaceuticals class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Rocket Pharmaceuticals class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 [email protected]

Yahoo

13 hours ago

• Yahoo

Lumen (LUMN) Subsidiary to Raise $1B for AI-Focused Debt Refinancing

Lumen Technologies, Inc. (NYSE:LUMN) is one of the 11 must-buy AI stocks analysts are betting on. On June 16, the company announced its wholly owned subsidiary Level 3 Financing plans to raise $1 billion in the market to refinance debt. An aerial view of a communications satellite in orbit, beaming its signal down to Earth. Level 3 will offer a $1 billion aggregate principal of First Lien Notes due in 2033. The unit will leverage net proceeds from the offering to redeem all $924.522 million in aggregate principal amount of senior secured notes due in 2030. The refinancing move extends the maturity date of Level 3 financing debt from 2030 to 2033. Lumen Technologies, Inc. (NYSE:LUMN) is a global communications and IT services company that offers solutions that help businesses connect people's data and applications securely. Its solutions also help companies realize artificial intelligence potential through its metro connectivity edge cloud and managed service capabilities. While we acknowledge the potential of LUMN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 12 Best Healthcare Stocks to Buy Now and 10 Stocks Analysts Are Upgrading Today. Disclosure: None. Sign in to access your portfolio